NGM Biopharmaceuticals, Inc.
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
Last updated:
Abstract:
Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Status:
Grant
Type:
Utility
Filling date:
27 May 2015
Issue date:
3 Sep 2019